Keros Therapeutics (KROS) Research & Development (2019 - 2025)
Historic Research & Development for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $19.5 million.
- Keros Therapeutics' Research & Development fell 6034.74% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.4 million, marking a year-over-year decrease of 491.2%. This contributed to the annual value of $173.6 million for FY2024, which is 2836.87% up from last year.
- Per Keros Therapeutics' latest filing, its Research & Development stood at $19.5 million for Q3 2025, which was down 6034.74% from $43.5 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Research & Development ranged from a high of $49.2 million in Q3 2024 and a low of $10.0 million during Q2 2021
- Moreover, its 5-year median value for Research & Development was $31.1 million (2023), whereas its average is $29.6 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 13320.65% in 2022, then plummeted by 6034.74% in 2025.
- Over the past 5 years, Keros Therapeutics' Research & Development (Quarter) stood at $18.8 million in 2021, then soared by 32.04% to $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then increased by 21.71% to $45.6 million in 2024, then plummeted by 57.22% to $19.5 million in 2025.
- Its last three reported values are $19.5 million in Q3 2025, $43.5 million for Q2 2025, and $48.7 million during Q1 2025.